$CTOR
CITIUS ONCOLOGY, INC. Stock $ctor

$ctor Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000149315223042170 Filed on November 20, 2023

Income Statement

Concept	2023 Q4	2023 Q3	2022 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$244.1K	$421.5K
YoY Change	76.76%
% of Gross Profit
Research & Development	$1.148M
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$244.1K	$421.5K	$0.00
YoY Change	76.76%
Operating Profit		-$421.5K
YoY Change
Interest Expense	$1.277M	$579.4K
YoY Change	146.18%
% of Operating Profit
Other Income/Expense, Net	$30.37K	$579.4K
YoY Change
Pretax Income	$1.033M	$157.9K	$0.00
YoY Change	171.35%
Income Tax	$144.0K
% Of Pretax Income	13.94%
Net Earnings	$1.033M	$157.9K
YoY Change	171.35%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.07	$0.02	$0.00
Diluted Earnings Per Share	$0.12	$0.02	$0.00
COMMON SHARES
Basic Shares Outstanding	8.941M shares	8.941M shares	1.500M shares
Diluted Shares Outstanding	67.50M shares	6.600M shares	1.500M shares

Balance Sheet

Concept	2023 Q4	2023 Q3	2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$32.75K	$26.52K
YoY Change	-88.67%
Cash & Equivalents	$32.75K	$26.52K
Short-Term Investments
Other Short-Term Assets	$25.45K	$58.63K
YoY Change	-71.14%
Inventory
Prepaid Expenses	$25.45K	$58.63K
Receivables
Other Receivables
Total Short-Term Assets	$58.20K	$85.16K
YoY Change	-84.58%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$72.57M	$70.63M
YoY Change	7.01%
Other Assets			$256.7K
YoY Change
Total Long-Term Assets	$72.57M	$70.63M
YoY Change	7.01%
TOTAL ASSETS
Total Short-Term Assets	$58.20K	$85.16K
Total Long-Term Assets	$72.57M	$70.63M
Total Assets	$72.62M	$70.71M	$256.7K
YoY Change	6.5%	27442.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$1.289M
YoY Change
Accrued Expenses	$375.9K	$383.7K	$73.69K
YoY Change	1080.55%	420.7%
Deferred Revenue
YoY Change
Short-Term Debt	$1.320M	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.046M	$1.169M	$266.9K
YoY Change	6325.94%	337.9%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$0.00	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.046M	$1.169M	$266.9K
Total Long-Term Liabilities	$0.00	$0.00	$0.00
Total Liabilities	$2.046M	$1.169M	$266.9K
YoY Change	6325.13%	337.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.988M	-$1.084M	-$10.11K
YoY Change	-675.71%	10614.82%
Common Stock	$167.00	$167.00	$173.00
YoY Change	-30.99%	-3.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.988M	-$1.083M	-$10.11K
YoY Change
Total Liabilities & Shareholders Equity	$72.62M	$70.71M	$256.7K
YoY Change	6.5%	27442.14%

Cashflow Statement

Concept	2023 Q4	2023 Q3	2022 Q3
OPERATING ACTIVITIES
Net Income	$1.033M	$157.9K
YoY Change	171.35%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$218.8K	-$112.5K	$0.00
YoY Change	356.06%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$660.0K	-$660.0K
YoY Change	-99.02%
Cash From Investing Activities	-$660.0K	-$660.0K
YoY Change	-99.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	885.0K	429.9K
YoY Change	-98.69%
NET CHANGE
Cash From Operating Activities	-218.8K	-112.5K	0.000
Cash From Investing Activities	-660.0K	-660.0K
Cash From Financing Activities	885.0K	429.9K
Net Change In Cash	6.230K	-342.6K	0.000
YoY Change	-97.85%
FREE CASH FLOW
Cash From Operating Activities	-$218.8K	-$112.5K	$0.00
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001851484
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent		usd
CY2023Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2023Q3	TENK	Shareholder Receivable ShareholderReceivable		usd
CY2022Q4	TENK	Shareholder Receivable ShareholderReceivable		usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss		usd
	us-gaap	Operating Income Loss OperatingIncomeLoss		usd
CY2022Q3	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust		usd
	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust		usd
CY2022Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense		usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense		usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss		usd
	us-gaap	Net Income Loss NetIncomeLoss		usd
CY2022Q3	TENK	Weighted Average Ordinary Shares Outstanding Basic For Ordinary Shares Subject To Redemption WeightedAverageOrdinarySharesOutstandingBasicForOrdinarySharesSubjectToRedemption		shares
CY2022Q3	TENK	Weighted Average Ordinary Shares Outstanding Diluted For Ordinary Shares Subject To Redemption WeightedAverageOrdinarySharesOutstandingDilutedForOrdinarySharesSubjectToRedemption		shares
	TENK	Weighted Average Ordinary Shares Outstanding Basic For Ordinary Shares Subject To Redemption WeightedAverageOrdinarySharesOutstandingBasicForOrdinarySharesSubjectToRedemption		shares
	TENK	Weighted Average Ordinary Shares Outstanding Diluted For Ordinary Shares Subject To Redemption WeightedAverageOrdinarySharesOutstandingDilutedForOrdinarySharesSubjectToRedemption		shares
CY2023Q3	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss		usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss		usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss		usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss		usd
	us-gaap	Net Income Loss NetIncomeLoss		usd
	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust		usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense		usd
	TENK	Increase Decrease Formation And Organization Costs Paid By Related Parties IncreaseDecreaseFormationAndOrganizationCostsPaidByRelatedParties		usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities		usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect		usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations		usd
	TENK	Remeasurement Of Ordinary Shares Subject To Redemption RemeasurementOfOrdinarySharesSubjectToRedemption		usd
	TENK	Deferred Offering Costs Included In Accrued Expenses DeferredOfferingCostsIncludedInAccruedExpenses		usd
	TENK	Deferred Offering Costs Included In Due To Related Party DeferredOfferingCostsIncludedInDueToRelatedParty		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41534
	dei	Entity Registrant Name EntityRegistrantName	TenX Keane Acquisition
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	E9
	dei	Entity Address Address Line1 EntityAddressAddressLine1	420 Lexington Ave
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 2446
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10170
	dei	City Area Code CityAreaCode	(347)
	dei	Local Phone Number LocalPhoneNumber	627-0058
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
	dei	Entity Shell Company EntityShellCompany	true
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	8941000	shares
CY2023Q3	us-gaap	Cash Cash	26523	usd
CY2022Q4	us-gaap	Cash Cash	289175	usd
CY2023Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	58633	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	88169	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	85156	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	377344	usd
CY2023Q3	us-gaap	Long Term Investments LongTermInvestments	70627915	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	67813020	usd
CY2023Q3	us-gaap	Assets Assets	70713071	usd
CY2022Q4	us-gaap	Assets Assets	68190364	usd
CY2023Q3	TENK	Accrued Offering Costs AccruedOfferingCosts	5001	usd
CY2022Q4	TENK	Accrued Offering Costs AccruedOfferingCosts	31836	usd
CY2023Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	383703	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1168579	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	31836	usd
CY2023Q3	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	6600000	shares
CY2022Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	6600000	shares
CY2023Q3	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	10.70
CY2022Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	10.27
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	70627915	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	67813020	usd
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2341000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2341000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2341000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2341000	shares
CY2023Q3	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	6600000	shares
CY2022Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Number Of Shares SharesSubjectToMandatoryRedemptionSettlementTermsNumberOfShares	6600000	shares
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	167	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	242	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1083590	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	345266	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1083423	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	345508	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	70713071	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	68190364	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	421455	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	768931	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-421455	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-768931	usd
CY2023Q3	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust	579398	usd
	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust	2154895	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	579398	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2154895	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	157943	usd
	us-gaap	Net Income Loss NetIncomeLoss	1385964	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6600000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6600000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1500000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1500000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6600000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6600000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1500000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1500000	shares
CY2023Q3	TENK	Basic Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption BasicNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.02
CY2023Q3	TENK	Diluted Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption DilutedNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.02
CY2022Q3	TENK	Basic Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption BasicNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.00
CY2022Q3	TENK	Diluted Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption DilutedNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.00
	TENK	Basic Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption BasicNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.14
	TENK	Diluted Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption DilutedNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.14
	TENK	Basic Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption BasicNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.00
	TENK	Diluted Net Income Per Ordinary Share For Ordinary Shares Not Subject To Redemption DilutedNetIncomePerOrdinaryShareForOrdinarySharesNotSubjectToRedemption	0.00
CY2023Q3	TENK	Weighted Average Ordinary Shares Outstanding Basic For Ordinary Shares Subject To Redemption WeightedAverageOrdinarySharesOutstandingBasicForOrdinarySharesSubjectToRedemption	2341815	shares
CY2023Q3	TENK	Weighted Average Ordinary Shares Outstanding Diluted For Ordinary Shares Subject To Redemption WeightedAverageOrdinarySharesOutstandingDilutedForOrdinarySharesSubjectToRedemption	2341815	shares
	TENK	Weighted Average Ordinary Shares Outstanding Basic For Ordinary Shares Subject To Redemption WeightedAverageOrdinarySharesOutstandingBasicForOrdinarySharesSubjectToRedemption	2391000	shares
	TENK	Weighted Average Ordinary Shares Outstanding Diluted For Ordinary Shares Subject To Redemption WeightedAverageOrdinarySharesOutstandingDilutedForOrdinarySharesSubjectToRedemption	2391000	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.02
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.15
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.15
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.00
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.00
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	345508	usd
CY2023Q1	TENK	Adjustments To Retained Earnings Remeasurement Of Ordinary Shares Subject To Redemption AdjustmentsToRetainedEarningsRemeasurementOfOrdinarySharesSubjectToRedemption	-759647	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	611725	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	197586	usd
CY2023Q2	TENK	Adjustments To Retained Earnings Remeasurement Of Ordinary Shares Subject To Redemption AdjustmentsToRetainedEarningsRemeasurementOfOrdinarySharesSubjectToRedemption	-815850	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	616296	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-1968	usd
CY2023Q3	TENK	Adjustments To Retained Earnings Remeasurement Of Ordinary Shares Subject To Redemption AdjustmentsToRetainedEarningsRemeasurementOfOrdinarySharesSubjectToRedemption	-1239398	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	157943	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	-1083423	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	-10113	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-10113	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-10113	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	-10113	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-10113	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	-10113	usd
	us-gaap	Net Income Loss NetIncomeLoss	1385964	usd
	TENK	Interest Income On Investments Held In Trust InterestIncomeOnInvestmentsHeldInTrust	2154895	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-29536	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	356868	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-382527	usd
	us-gaap	Payments To Acquire Other Investments PaymentsToAcquireOtherInvestments	660000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-660000	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	779875	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	779875	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-262652	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	289175	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	26523	usd
	TENK	Remeasurement Of Ordinary Shares Subject To Redemption RemeasurementOfOrdinarySharesSubjectToRedemption	2814895	usd
	TENK	Deferred Offering Costs Included In Accrued Expenses DeferredOfferingCostsIncludedInAccruedExpenses	67846	usd
	TENK	Deferred Offering Costs Included In Due To Related Party DeferredOfferingCostsIncludedInDueToRelatedParty	62477	usd
CY2022Q4	TENK	Condition For Future Business Combination Use Of Proceeds Percentage ConditionForFutureBusinessCombinationUseOfProceedsPercentage	0.80	pure
CY2022Q4	TENK	Condition For Future Business Combination Threshold Percentage Ownership ConditionForFutureBusinessCombinationThresholdPercentageOwnership	0.50	pure
CY2022Q4	TENK	Redemption Limit Percentage Without Prior Written Consent RedemptionLimitPercentageWithoutPriorWrittenConsent	0.15	pure
CY2022Q4	TENK	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
CY2022Q4	TENK	Percentage Obligation To Redeem Public Shares If Entity Does Not Complete Business Combination PercentageObligationToRedeemPublicSharesIfEntityDoesNotCompleteBusinessCombination	1	pure
CY2022Q4	TENK	Maximum Allowed Dissolution Expenses MaximumAllowedDissolutionExpenses	100000	usd
CY2023Q3	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	2416000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	2416000	shares
CY2022Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	2416000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_848_eus-gaap--UseOfEstimates_zKiKb6xrYTIa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_861_zJuJtAbHvkf9">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q3	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	usd
CY2022Q4	us-gaap	Deferred Offering Costs DeferredOfferingCosts	0	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2022Q3	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	225000	shares
CY2022Q4	us-gaap	Payments For Underwriting Expense PaymentsForUnderwritingExpense	2922480	usd
CY2022Q4	us-gaap	Shares Subject To Mandatory Redemption Settlement Terms Amount SharesSubjectToMandatoryRedemptionSettlementTermsAmount	66000000	usd
CY2022Q4	TENK	Proceeds Allocated To Public Rights ProceedsAllocatedToPublicRights	-1056000	usd
CY2022Q4	TENK	Offering Costs Allocated Ordinary Shares Subject To Redemption OfferingCostsAllocatedOrdinarySharesSubjectToRedemption	-4755805	usd
CY2022Q4	TENK	Temporary Equity Accrued Interest In Trust TemporaryEquityAccruedInterestInTrust	7624825	usd
CY2022Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	67813020	usd
CY2023Q1	TENK	Temporary Equity Accrued Interest In Trust TemporaryEquityAccruedInterestInTrust	759647	usd
CY2023Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	68572667	usd
CY2023Q2	TENK	Temporary Equity Accrued Interest In Trusts TemporaryEquityAccruedInterestInTrusts	815850	usd
CY2023Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	69388517	usd
CY2023Q3	TENK	Temporary Equity Accrued Interest In Trusts TemporaryEquityAccruedInterestInTrusts	1239398	usd
CY2023Q3	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	70627915	usd
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zyIXlDQkDaN7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_866_zWaTikVr4DS8">Concentration of Credit Risk</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution, which, at times, may exceed the Federal Depository Insurance Coverage of $<span id="xdx_905_eus-gaap--CashFDICInsuredAmount_iI_c20230930_zaT3U2oqybtd" title="FDIC insured amount">250,000</span>. The Company has not experienced losses on this account.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	12.00
CY2023Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	30000	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	90000	usd
CY2022Q3	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	0	usd
	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	0	usd
CY2023Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	30000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	0	usd
CY2023Q3	us-gaap	Share Price SharePrice	10.00
CY2023Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q3	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	2416000	shares

Files In Submission

Name	View Source	Status
0001493152-23-042170-index-headers.html	Edgar Link	pending
0001493152-23-042170-index.html	Edgar Link	pending
0001493152-23-042170.txt	Edgar Link	pending
0001493152-23-042170-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tenk-20230930.xsd	Edgar Link	pending
tenk-20230930_def.xml	Edgar Link	unprocessable
tenk-20230930_lab.xml	Edgar Link	unprocessable
tenk-20230930_cal.xml	Edgar Link	unprocessable
tenk-20230930_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CTOR
CITIUS ONCOLOGY, INC. Stock $ctor

2023 Q4 Form 10-Q Financial Statement

#000149315223042170 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTOR CITIUS ONCOLOGY, INC. Stock $ctor

2023 Q4 Form 10-Q Financial Statement

#000149315223042170 Filed on November 20, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CTOR
CITIUS ONCOLOGY, INC. Stock $ctor